The Africa Plasma-derived Therapies Market size was valued at USD 77.18 MN in 2021 and reached USD 106.73 MN in 2025. It is anticipated to reach USD 194.03 MN by 2032, growing at a CAGR of 7.45% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2021-2024
Base Year
2025
Forecast Period
2025-2032
Africa Plasma-derived Therapies Market Size 2025
USD 106.73 million
Africa Plasma-derived Therapies Market, CAGR
7.45%
Africa Plasma-derived Therapies Market Size 2032
USD 194.03 million
Africa Plasma-derived Therapies Market Insights
Market growth is supported by rising need for plasma-derived medicinal products, underpenetrated haemophilia care, immunoglobulin demand, albumin use in acute care and gradual strengthening of blood product access systems.
Immunoglobulin holds a strong position because Primary Immunodeficiency Disease and immune-mediated conditions require long-term replacement therapy and specialist-supervised treatment.
Coagulation Factors remain critical for Haemophilia care because patients require reliable factor replacement access to prevent or manage bleeding episodes.
Hospital-based treatment remains central because plasma-derived therapies require diagnosis, cold-chain handling, clinical monitoring and safe administration.
Africa Plasma-derived Therapies Market Segment Insights
By product type
By product type, Immunoglobulin held the strongest position in 2025 because it supports long-term treatment of Primary Immunodeficiency Disease and selected immune-mediated conditions. Demand is concentrated in larger hospitals and specialist centers where diagnosis, dosing, infusion monitoring and cold-chain systems are available. Coagulation Factors remain essential for Haemophilia because factor replacement therapy supports bleeding control, perioperative management and long-term care. Albumin supports acute care, critical care, liver disease management, shock, burns and volume replacement in selected settings. Growth across product types will depend on diagnosis rates, affordability, public procurement, hospital access and reliable plasma-derived medicinal product supply.
By application type
By application type, Haemophilia held a strong position in 2025 because factor replacement remains a core treatment need for patients with inherited bleeding disorders. Access gaps across Africa create significant unmet demand, especially outside major urban hospitals. Primary Immunodeficiency Disease is gaining attention as immunology diagnosis improves and clinicians recognize patients who need immunoglobulin replacement therapy. Idiopathic Thrombocytopenic Purpura supports demand for immunoglobulin in acute immune-mediated platelet disorders and specialist hematology care. Application growth will depend on hematology capacity, immunology testing, patient registries, public reimbursement and donor-supported access programs.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Need for safe and sufficient blood products represents a major growth driver for the Africa Plasma-derived Therapies Market. Plasma-derived medicinal products such as immunoglobulins and coagulation factors treat serious conditions that require dependable supply and high quality standards.
WHO reported that governments are responsible for sufficient and equitable supply of plasma-derived medicinal products, and only 49 of 168 reporting countries produced plasma-derived medicinal products through domestic plasma fractionation, while 119 countries imported all PDMPs or did not use them during the reporting period. This supports demand for Immunoglobulin, Coagulation Factors and Hospital-based access models across Africa. Growth will depend on stronger national blood systems, procurement planning, import reliability and safe distribution.
Haemophilia and immune deficiency treatment need
Haemophilia and immune deficiency treatment need supports strong demand for Coagulation Factors and Immunoglobulin. WHO says blood and plasma-derived medical products can dramatically improve life expectancy and quality of life for patients with life-threatening inherited disorders such as haemophilia and immune deficiency. This creates sustained demand across Haemophilia and Primary Immunodeficiency Disease, especially as diagnosis improves in referral hospitals. The market remains underpenetrated because many patients still face delayed diagnosis, limited specialist access and affordability barriers. Expanding hematology and immunology services will support broader use of plasma-derived therapies through 2032.
Growing concern over PDMP access in Africa
Growing concern over PDMP access in Africa is strengthening policy attention and market need. WHO’s 2022 survey report on blood availability, safety and quality in the WHO African Region raised concern about the growing need for plasma-derived medicinal products in Africa.
WHO Africa also reported that 30 countries listed plasma-derived medicinal products on their essential medicines lists, while patients in the region paid an average of USD 42 out of pocket to access safe blood. These figures show both demand recognition and affordability pressure. The driver supports Hospital access, public procurement and payer-led expansion of essential plasma-derived therapies.
Global company investment in plasma-derived portfolios
Global company investment in plasma-derived portfolios supports supply depth and future access in Africa. CSL reported 2025 CSL Behring revenue of USD 6.064 billion for Immunoglobulins, USD 1.297 billion for Albumin and USD 1.488 billion for Haemophilia products. Takeda reported Plasma-Derived Therapies revenue of 517.4 billion yen in the first half of fiscal 2025 and said immunoglobulin grew 3.1% at constant exchange rates, with demand remaining strong. These company trends support long-term supply, portfolio investment and broader availability of Immunoglobulin, Albumin and Coagulation Factors. Africa’s market will benefit as global manufacturers strengthen distribution partnerships and access programs.
Key Trends and Opportunities
Local plasma access and fractionation partnerships gain attention
Local plasma access and fractionation partnerships are gaining attention as African health systems seek more reliable access to plasma-derived medicinal products. WHO’s blood safety guidance emphasizes national blood systems, voluntary unpaid donation, plasma collection and processing systems that meet health care needs. Partnerships with global fractionators can help countries use domestic plasma more effectively where quality systems and regulatory controls support safe production. This trend supports Immunoglobulin, Coagulation Factors and Albumin. Growth will depend on donor recruitment, plasma quality, testing systems, regulatory oversight and commercial feasibility.
Immunoglobulin demand expands in specialty care
Immunoglobulin demand is expanding in specialty care as diagnosis of Primary Immunodeficiency Disease and immune-mediated disorders improves. Immunoglobulin therapy requires repeat dosing, specialist oversight and reliable product availability, making hospital and specialty-center access critical. ADMA Biologics reported full-year 2025 ASCENIV revenue of USD 363 million, up 51% year over year, and said it manufactures FDA-approved plasma-derived biologics for immune deficiencies and prevention of certain infectious diseases. This global commercial momentum supports wider recognition of immunoglobulin therapies. African demand will expand as immunology testing, physician awareness and reimbursement improve.
Albumin and coagulation factors support hospital formularies
Albumin and Coagulation Factors support hospital formularies because they serve acute care, hematology, surgery and inherited bleeding disorder needs. Grifols reported 2025 revenue of EUR 7.524 billion, up 7.0% at constant currency, driven by its Biopharma business and immunoglobulin franchise. It also reported EMA approval for Egypt-sourced plasma and fibrinogen approval by EMA and FDA. This is significant for Africa because Egypt-sourced plasma approval supports regional plasma infrastructure and validates the role of regional supply models. Hospitals with better procurement systems will be better positioned to add plasma-derived therapies to formularies.
Key Market Challenges
High cost and out-of-pocket burden
High cost and out-of-pocket burden remain major challenges for the Africa Plasma-derived Therapies Market. Plasma-derived therapies require complex plasma collection, testing, fractionation, viral safety controls, cold-chain distribution and specialist administration. These cost layers can limit public procurement and patient access. WHO Africa reported that patients in the region paid an average of USD 42 out of pocket to access safe blood, showing broader affordability pressure around blood products and related care. Immunoglobulin and coagulation factors are particularly vulnerable because they often require repeated treatment. Access programs, pooled procurement and donor-supported initiatives will remain important.
Cold-chain and quality system constraints
Cold-chain and quality system constraints can slow market expansion. Plasma-derived therapies require controlled storage, validated transport, batch traceability and hospital-level handling protocols. WHO says national blood systems should be governed by policy and legislative frameworks that promote consistency in quality and safety of blood and blood products. It also recommends quality-assured screening and systems for processing blood into blood products, including plasma-derived medicinal products. Many lower-resource settings still face gaps in testing, storage, distribution and haemovigilance. These constraints affect Immunoglobulin, Coagulation Factors and Albumin access.
Limited diagnosis and specialist capacity
Limited diagnosis and specialist capacity restrict therapy uptake. Haemophilia, Primary Immunodeficiency Disease and Idiopathic Thrombocytopenic Purpura require hematologists, immunologists, laboratory testing and structured follow-up. Patients in rural areas may remain undiagnosed or reach care only after severe complications. Hospital access is stronger in South Africa, Egypt, Kenya, Nigeria and large urban centers, but smaller markets face larger gaps. Limited patient registries make forecasting and procurement difficult. Companies and health systems must support clinician education, diagnostic pathways and treatment centers to expand demand responsibly.
Regional Analysis
South Africa
South Africa leads the Africa Plasma-derived Therapies Market due to stronger blood product regulation, specialist hospitals, hematology expertise and private insurance access. Hospitals manage Immunoglobulin, Coagulation Factors and Albumin through structured procurement and monitored administration. South Africa also has stronger experience with plasma-derived medicinal products than many regional peers. WHO’s global blood data show that government responsibility, national blood systems and safe plasma-derived product supply remain central to access, which aligns with South Africa’s more advanced market position. Growth will depend on reimbursement, public procurement, specialist capacity and supply continuity.
Egypt
Egypt represents a strong growth market due to large population, expanding tertiary hospitals and rising relevance in regional plasma infrastructure. Grifols reported EMA approval for Egypt-sourced plasma in 2025 and described it as a paradigm shift in the industry, reinforcing Egypt’s strategic role in plasma-derived medicine supply. Demand is supported by Albumin, Coagulation Factors and Immunoglobulin across hospitals and specialty hematology care. Growth will depend on regulatory execution, hospital access, public procurement and supply partnerships.
Nigeria
Nigeria offers long-term potential due to its large population and unmet need in hematology, immunology and critical care. Haemophilia and Primary Immunodeficiency Disease remain underdiagnosed, while Albumin demand is concentrated in larger private and public hospitals. Access constraints remain significant due to affordability, cold-chain infrastructure and limited specialist networks. Hospital procurement will remain the main access pathway for plasma-derived therapies. Growth will depend on diagnostic capacity, insurance expansion, public-sector procurement, donor support and private hospital investment.
Kenya
Kenya is an emerging market supported by growing specialist care, regional referral hospitals and improving private health care access. Demand is concentrated in Haemophilia, Primary Immunodeficiency Disease and acute hospital use of Albumin. Hospital systems remain the primary channel because plasma-derived therapies need specialist diagnosis and safe administration. Kenya can serve as an East African access hub if cold-chain logistics, regulation and payer coverage improve. Growth will depend on hematology networks, immunology testing, procurement reliability and manufacturer access programs.
Rest of Africa
Rest of Africa includes markets with diverse blood product capacity, funding levels and hospital access. Countries with stronger tertiary hospitals are expected to adopt plasma-derived therapies faster, while lower-resource countries may prioritize blood safety, donor recruitment and essential blood product access before broader PDMP use. WHO reported that 36 countries in the African Region were among countries collecting fewer than 10 blood donations per 1,000 people, highlighting supply constraints that affect blood product access. Long-term growth will depend on national blood policy, regional procurement, donor programs, regulatory oversight and hospital pharmacy readiness.
Report Attribute Details
Report Attribute
Details
Historical Period
2021–2024
Base Year
2025
Forecast Period
2025–2032
Market Size in 2021
USD 77.18 MN
Market Size in 2025
USD 106.73 MN
Market Size in 2032
USD 194.03 MN
CAGR
7.45%
Segments Covered
Product Type, Application Type and Geography
Key Companies Covered
ADMA Biologics, Inc., Bio Products Laboratory (BPL), CSL Behring, Grifols, S.A. (Biotest AG), Kamada Ltd., Kedrion SpA, Octapharma AG, Pfizer, Inc., SK Plasma and Takeda Pharmaceutical Co. Ltd.
Africa Plasma-derived Therapies Market Segmentations
By Product Type
Immunoglobulin
Coagulation Factors
Albumin
By Application Type
Haemophilia
Primary Immunodeficiency Disease
Idiopathic Thrombocytopenic Purpura
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In February 2026, Grifols reported 2025 revenue of EUR 7.524 billion, up 7.0% at constant currency, driven by its Biopharma business and immunoglobulin franchise. It also reported EMA approval for Egypt-sourced plasma and fibrinogen approval by EMA and FDA.
In February 2026, ADMA Biologics reported full-year 2025 ASCENIV revenue of USD 363 million, up 51% year over year, and expanded access through a new authorized distribution agreement with McKesson Specialty for ASCENIV and BIVIGAM.
In February 2026, Octapharma reported 2025 group sales of EUR 3.64 billion, up 5% year over year, and operating income of EUR 577 million, supported by efficiency improvements and economies of scale in plasma collection and production.
In first-half fiscal 2025, Takeda reported Plasma-Derived Therapies revenue of 517.4 billion yen and said immunoglobulin grew 3.1% at constant exchange rates.
Report Coverage
The research report offers an in-depth analysis based on product type, application type and geography. It details leading market players, providing an overview of their business positioning, plasma-derived product portfolios, immunoglobulin capabilities, coagulation factor offerings, albumin supply, plasma collection networks, fractionation capacity and strategic relevance in the Africa Plasma-derived Therapies Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines blood product access, haemophilia treatment need, primary immunodeficiency diagnosis, hospital formularies, plasma supply constraints, cold-chain requirements and regional procurement models as major factors shaping market development. The report assesses the impact of high therapy cost, out-of-pocket burden, limited specialist capacity, quality system gaps and cold-chain constraints on market growth. It provides strategic recommendations for plasma-derived therapy manufacturers, hospitals, blood services, procurement agencies, distributors, payers, investors and new entrants seeking to navigate Africa’s plasma-derived therapies ecosystem.
Future Outlook
Demand for plasma-derived therapies will continue to rise as African health systems improve diagnosis and access for Haemophilia, Primary Immunodeficiency Disease and immune-mediated disorders.
Immunoglobulin will remain a leading product type due to long-term replacement therapy demand in Primary Immunodeficiency Disease.
Coagulation Factors will gain importance as haemophilia diagnosis, factor access and bleeding disorder care programs improve.
Albumin will remain important in hospitals because it supports acute care, critical care and selected volume replacement needs.
Haemophilia will remain a major application due to high unmet treatment needs and dependence on reliable factor access.
Primary Immunodeficiency Disease will expand as immunology testing and specialist awareness improve.
Idiopathic Thrombocytopenic Purpura will support demand for immunoglobulin in specialist hematology settings.
South Africa and Egypt will remain key markets due to stronger hospital infrastructure, regulatory capacity and plasma-derived product access.
Regional plasma programs and import partnerships will gain strategic value as countries seek reliable supply.
Competition will increase as companies compete on product quality, supply reliability, cold-chain strength, access programs, pricing and hospital procurement relationships.
Table of Contents (The complete Toc, LoF and LoT are available in the sample report)
Chapter No. 1: Introduction
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. USP and Key Offerings
1.2. Key Benefits for Stakeholders
1.3. Target Audience
Chapter No. 2: Executive Summary
Chapter No. 3: Africa Plasma-derived Therapies Market forces and industry pulse
3.1. Introduction
3.2. Catalysts of Expansion – Key Market Drivers
3.2.1. Need for safe and sufficient blood products
3.2.2. Haemophilia and immune deficiency treatment need
3.2.3. Growing concern over PDMP access in Africa
3.2.4. Global company investment in plasma-derived portfolios
3.3. Market Restraints
3.3.1. High cost and out-of-pocket burden
3.3.2. Cold-chain and quality system constraints
3.3.3. Limited diagnosis and specialist capacity
3.4. Untapped Horizons – Growth Potential and Opportunities; Strategic Navigation – Industry Frameworks
3.4.1. Local plasma access and fractionation partnerships gain attention
3.4.2. Immunoglobulin demand expands in specialty care
3.4.3. Albumin and coagulation factors support hospital formularies
Chapter No. 4: Competition Analysis
4.1. Company Market Share Analysis
4.1.1. Africa Plasma-derived Therapies Market Company Revenue Market Share, 2025
4.2. Strategic Developments
4.3. Competitive Dashboard
4.4. Company Assessment Metrics, 2025
Chapter No. 5: Africa Market Analysis, Insights and Forecast, by Product Type
Chapter No. 6: Africa Market Analysis, Insights and Forecast, by Application Type
Chapter No. 7: Africa Market Analysis, Insights and Forecast, by Geography
7.1. South Africa
7.2. Egypt
7.3. Nigeria
7.4. Kenya
7.5. Rest of Africa
Chapter No. 8: Company Profile
8.1. ADMA Biologics, Inc.
8.2. Bio Products Laboratory (BPL)
8.3. CSL Behring
8.4. Grifols, S.A. (Biotest AG)
8.5. Kamada Ltd.
8.6. Kedrion SpA
8.7. Octapharma AG
8.8. Pfizer, Inc.
8.9. SK Plasma
8.10. Takeda Pharmaceutical Co. Ltd.
List of figures
Fig No. 1: Africa Plasma-derived Therapies Market Revenue Share, by Product Type, 2025 and 2032
Fig No. 2: Market Attractiveness Analysis, by Product Type
Fig No. 3: Incremental Revenue Growth Opportunity by Product Type, 2025–2032
Fig No. 4: Africa Plasma-derived Therapies Market Revenue Share, by Application Type, 2025 and 2032
Fig No. 5: Incremental Revenue Growth Opportunity by Application Type, 2025–2032
Fig No. 6: Africa Plasma-derived Therapies Market Revenue Share, by Geography, 2025 and 2032
Fig No. 7: Market Attractiveness Analysis, by Geography
List of tables
Table No. 1: Africa Plasma-derived Therapies Market Revenue, by Product Type, 2021–2025 (USD MN)
Table No. 2: Africa Plasma-derived Therapies Market Revenue, by Product Type, 2026–2032 (USD MN)
Table No. 3: Africa Plasma-derived Therapies Market Revenue, by Application Type, 2021–2025 (USD MN)
Table No. 4: Africa Plasma-derived Therapies Market Revenue, by Application Type, 2026–2032 (USD MN)
Table No. 5: Africa Plasma-derived Therapies Market Revenue, by Geography, 2021–2025 (USD MN)
Table No. 6: Africa Plasma-derived Therapies Market Revenue, by Geography, 2026–2032 (USD MN)
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for the Africa Plasma-derived Therapies Market and what is its projected size in 2032?
The Africa Plasma-derived Therapies Market was valued at USD 106.73 MN in 2025 and is projected to reach USD 194.03 MN by 2032.
At what CAGR is the Africa Plasma-derived Therapies Market projected to grow?
The Africa Plasma-derived Therapies Market is projected to grow at a CAGR of 7.45% during the forecast period.
Which product type segment is expected to lead the market?
Immunoglobulin is expected to hold a strong position because Primary Immunodeficiency Disease and immune-mediated conditions require long-term replacement therapy and specialist-supervised treatment.
Which application type supports strong market demand?
Haemophilia supports strong market demand because patients require reliable coagulation factor access to prevent or manage bleeding episodes.
Which country leads the Africa market?
South Africa leads the market due to stronger blood product regulation, specialist hospitals, hematology expertise and private insurance access.
Who are the leading companies in the market?
The leading companies include ADMA Biologics, Inc., Bio Products Laboratory (BPL), CSL Behring, Grifols, S.A. (Biotest AG), Kamada Ltd., Kedrion SpA, Octapharma AG, Pfizer, Inc., SK Plasma and Takeda Pharmaceutical Co. Ltd.
What are the key challenges in the market?
The key challenges include high cost, out-of-pocket burden, cold-chain constraints, quality system gaps, limited diagnosis and specialist capacity.
Cell therapy consumables Market was valued at USD 3439 million in 2024 and is anticipated to reach USD 7533.31 million by 2032, growing at a CAGR of 10.3% during the forecast period.
The Asia Pacific RNA-based Therapeutics Market size was valued at USD 1,025.76 MN in 2021 and reached USD 1,749.49 MN in 2025. It is anticipated to reach USD 4,685.07 MN by 2032, growing at a CAGR of 12.57% during the forecast period.
3D Printed Nanocellulose Market was valued at USD 1171 million in 2026 and is anticipated to reach USD 3892 million by 2032, growing at a CAGR of 16.20% during the forecast period.
Balloon Infusers Market size was valued USD 2364 million in 2024 and is anticipated to reach USD 3575.3 million by 2032, at a CAGR of 5.31% during the forecast period.
DNA and RNA Sample Preparation Market size was valued at USD 2,210 million in 2024 and is anticipated to reach USD 4,265.72 million by 2032, growing at a CAGR of 8.57% during the forecast period.
The Elastomeric Infusion Pump market is projected to witness substantial growth, with its value expected to surge from USD 1,241 million in 2023 to USD 2,646 million by 2032, reflecting a remarkable compound annual growth rate of 8.14%. T
The global wheat starch market was valued at USD 5,118.6 million in 2024 and is projected to reach USD 7,505.08 million by 2032, expanding at a compound annual growth rate (CAGR) of 4.9% during the forecast period
The Crohn's Disease Treatment Market size was valued at USD 11,920 million in 2024 and is anticipated to reach USD 15,478.65 million by 2032, growing at a CAGR of 3.32% during the forecast period.
The Australia Shop Fitting Contractors Market size was valued at USD 420.36 MN in 2021 and reached USD 549.54 MN in 2025. It is anticipated to reach USD 1,029.63 MN by 2035, growing at a calculated CAGR of 6.48% during the forecast period.
The Asia Pacific Monoclonal Antibodies Market size was valued at USD 40,541.17 MN in 2021 and reached USD 64,255.32 MN in 2025. It is anticipated to reach USD 149,792.56 MN by 2032, growing at a CAGR of 10.70% during the forecast period.
The Africa Orphan Drugs Market size was valued at USD 792.75 MN in 2021 and reached USD 1,258.16 MN in 2025. It is anticipated to reach USD 2,826.51 MN by 2032, growing at a CAGR of 6.30% during the forecast period.
The Middle East Vaccines Market size was valued at USD 873.98 MN in 2021 and reached USD 1,325.11 MN in 2025. It is anticipated to reach USD 2,813.55 MN by 2032, growing at a CAGR of 9.44% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
